Advancements in combination therapy of Hepatitis C virus | [Pakistan Journal of Pharmaceutical Sciences • 2020]

Author(s):

1. Muhammad Jahangeer: Department of Biochemistry, Government College University Faisalabad,Faisalabad,Pakistan

2. Nighat Zia ud Din: Department of Biochemistry, Government College University Faisalabad,Faisalabad,Pakistan

3. Sana Karim: Department of Biochemistry, Government College University Faisalabad,Faisalabad,Pakistan

4. Shoukat Hussain: Department of Biochemistry, Government College University Faisalabad,Faisalabad,Pakistan

5. Mehvish Ashiq: Department of Chemistry, The Women University Multan, Multan, Pakistan

6. Usman Ali: Department of Biochemistry, Government College University Faisalabad,Faisalabad,Pakistan

7. Anwar ul Haq: Department of Biochemistry, Government College University Faisalabad,Faisalabad,Pakistan

8. Naveed Munir: Department of Biochemistry, Government College University Faisalabad,Faisalabad,Pakistan

9. Zahed Mahmood: Department of Biochemistry, Government College University Faisalabad,Faisalabad,Pakistan

10. Abdul Ghaffar: Department of Biochemistry, Government College University Faisalabad,Faisalabad,Pakistan

Abstract:

Hepatitis C virus (HCV) is a primary cause of chronic liver disease along with various complications like liver cirrhosis and malignancy which leads to death. It has infected more than 185 million people worldwide. There is no congruence established for the treatment of various genotypes of HCV infection owing to diversity in prevalence globally. Assessment of affected individuals with HCV by polymerase chain reaction (PCR), viral load of HCV and liver enzyme levels (i.e., ALT and AST) are the foundation to evaluate the safety and efficacy of HCV therapies. The antiviral efficacy has been greatly improved and sustained viral response (SVR) rates increased from 6% with interferon monotherapy to 50-80% with PEG-interferon/ribavirin combination therapy to >95% after the approval of all interferon free oral direct acting antiviral agents. The main objective of this review article is to compile data from reference sources regarding the old and current therapeutic strategies used to manage HCV infection. It is accepted that chronic HCV infection increases patient's thrombocytopenia and neutropenia risk and complications increased in co-morbid disorders like in tuberculosis, HIV, diabetes etc. In past treatment associated side effects were the major consequences and many patients have to stop the treatment. But after the approval of direct acting antiviral drugs create a revolution in the treatment of HCV infection. So, it could be concluded that current combination therapies are a promising hope to eradicate and to control HCV but some safety concerns required more considerations Therefore, this review focus on the available latest combination therapies and their effectiveness to eradicate HCV infection.

Page(s): 2171-2178

DOI: DOI not available

Published: Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 33, Issue: 5, Year: 2020

Keywords:

Safety , Efficacy , ribavirin , Interferon , Direct Acting Antiviral Agents , Sustained viral response

References:

References are not available for this document.

Citations

Citations are not available for this document.

Citations

Downloads

Views